RA Pharmaceuticals presents pre-clinical data for zilucoplan XR
Ra Pharmaceuticals presented pre-clinical data for an extended release formulation of zilucoplan at the 6th Annual Peptides Congress in London. This XR formulation of zilucoplan employs PLGA technology, an established delivery platform for sustained release of peptides. In pre-clinical studies, the PLGA XR formulation of zilucoplan achieved and maintained therapeutic drug levels necessary to treat complement-mediated diseases, including generalized myasthenia gravis. Weekly subcutaneous doses of the PLGA XR formulation of zilucoplan in non-human primates rapidly achieved and maintained target drug concentrations for 14 days. Near-complete inhibition of complement component 5 in an ex vivo hemolysis assay was sustained throughout this 14 day period. Simon Read, Chief Scientific Officer of Ra Pharma, stated, "(...) we remain on track to advance the zilucoplan XR program into the clinic in the first half of 2020."